Dr. Bruno Osterwalder

Dr. Bruno Osterwalder has vast experience in assessing and selecting new, promising and commercially attractive oncology compounds with a special focus on immuno-oncology drug candidates. He is a proven leader in managing a portfolio of promising drug candidates and enabling key strategic decisions.

Dr Osterwalder is a graduate of the University of Zurich, a board-certified hematologist and oncologist with 15 years of academic & clinical experience in internal medicine, hematology and oncology. Following his academic career, Dr. Osterwalder spent 19 years increasing his scientific and managerial responsibilities in global drug development and strategic portfolio management at F. Hoffmann-La Roche in Basel, Switzerland, focusing on hematology, oncology and nephrology. Afterwards, he joined Merck Serono, Germany, as SVP responsible for global hemato-oncology and immuno-oncology drug development with a focus on early POC stages, translational medicine issues, drug development in China and Japan and provided strategic portfolio advice to top management. He has a deep understanding of all modern drug development stages from research transitioning to humans, to global registrations and life cycle management with NCE’s and NBE’s, including immunotherapeutics and vaccines. As a key member of Business Development teams, steering committees and advisory boards, Dr. Osterwalder assessed and analyzed early research and clinical programs and company portfolios. His numerous interactions with regulatory authorities included the US, EU, Japan, Australia and Canada which has led to successful worldwide registrations for several hemato-oncology compounds and an anemia treatment compound.